Membranous levels of c-erbB-2 oncoprotein in gastric cancer: Their relationship with clinicopathological parameters and their prognostic significance

Fj, Vizoso; Corte,; Alvarez, A. M.; García, I; Jm, del Casar Lizcano; Bongera, Miguel; Jl, García-Muñíz; Mt, Allende

doi:10.5301/jbm.2008.2535

Cited by 8 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intestinal Grabsch et al, 11 Marx et al, 15 Barros-Silva et al, 16 Zhang et al, 18 Matsubara et al, 20 Hayashi et al, 22 Park et al, 24 SatirogluTufan et al, 25 Tanner et al, 26 Vizoso et al, 28 Lee et al, 32 Oshima et al 38 [18 Studies (6 studies between 1990 and 1999 not displayed)]…”

Section: Lauren Classificationmentioning

confidence: 99%

Clinicopathologic factors associated with HER2‐positive gastric cancer and its impact on survival outcomes—A systematic review

Chua

Merrett

2011

Intl Journal of Cancer

163

111

View full text Add to dashboard Cite

With the availability of a therapeutic target and an effective agent in trastuzumab, a systematic examination of the literature to investigate the role of human epidermal growth factor 2 (HER2) as a prognostic factor for survival and its association with clinicopathologic markers may improve treatment. An electronic search of the MEDLINE and PubMed databases (January 1990 to January 2011) was undertaken to identify translational studies that correlated HER2 with clinicopathologic markers and/or survival outcome. This review included 49 studies totaling 11,337 patients. Forty-four percent of patients had Stage I/II, and 56% had Stage III/IV disease. Immunohistochemistry was most commonly used to assess HER2 expression, identifying a median rate of 18% (range, 4-53%) of gastric cancer demonstrating HER2 overexpression. In patients with and without HER2 overexpression, the median 3-year disease-free survival rate was 58% (range, 50-88%) and 86% (range, 62-97%), respectively. Of the 35 studies reporting the impact of HER2 overexpression on survival, 20 studies (57%) reported no difference in overall survival, two studies (6%) reported significantly longer overall survival in patients with HER2 overexpression and 13 studies (37%) reported significantly poorer overall survival in patients with HER2 overexpression. The median overall survival and 5-year survival rate was 21 (range, 10-57) months and 42%, and 33 (range, 13-80) months and 52% in patients with and without HER2 overexpression, respectively. HER2 overexpression appears to be associated with poorer survival and with intestinal-type gastric cancer in this group of patients for whom majority undergone curative gastrectomy.On a global scale, gastric cancer remains the second most common cause of cancer-related death with an estimated 930,000 new cases diagnosed each year albeit an overall decline in incidence. 1 Noncardia gastric cancers have steadily declined. However, it has been observed that proximal gastric cancers (cardia and oesophago-gastric tumors) are increasing at a rate of up to 10% per year, far exceeding that of any other type of cancer. Metastatic or advanced unresectable gastric cancer is an aggressive malignancy with a poor prognosis despite chemotherapy treatment with median survival of 7.5 to 12 months and a median survival of 3 to 5 months if managed by best supportive care. 2 Gastric cancer is a chemosensitive disease where a range of chemotherapy agents may achieve response rates of 30 to 40%; however, in the advanced setting, the disease is limited by a low complete response rate and the response duration is protracted often leading to disease progression and treatment related toxicities. 3 Combination chemotherapy with a Japanese standard doublet of fluoropyrimidine and platinum or western triplet regimens has shown better response rates and outcomes over single agent chemotherapy. However, there remains no established global standard for treatment.The human epidermal growth factor 2 (HER2) gene is a proto-oncogene where high amplifica...

show abstract

Section: Lauren Classificationmentioning

confidence: 99%

Clinicopathologic factors associated with HER2‐positive gastric cancer and its impact on survival outcomes—A systematic review

Chua

Merrett

2011

Intl Journal of Cancer

163

111

View full text Add to dashboard Cite

show abstract

“…Gene ampliWcation with increased expression of the protein is the most frequent HER2 abnormality detected in cancer (Moasser 2007). Overexpression of HER2 has been observed in various solid tumors, including breast (Kaptain et al 2001), colon (Half et al 2004), and stomach (Vizoso et al 2004). While HER2 signal propagated from the cell surface to intracellular eVectors needs signal transducers, including Grb2.…”

Section: Introductionmentioning

confidence: 98%

Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance

Chen

Wang

2009

J Cancer Res Clin Oncol

108

View full text Add to dashboard Cite

show abstract

“…Amplification of the EGF-R and/or the HER2/NEU oncogenes, and over-expression of their proteins, have been reported at various levels in gastric adenocarcinoma (15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26). In fact, correlations between Her-2/neu protein overexpression and HER2/NEU gene amplification have been reported (49)(50)(51)(52), and overexpression of Her-2/neu appears to be an independent prognostic factor in gastric cancer (18,(45)(46)(47)(48).…”

Section: Discussionmentioning

confidence: 99%

“…In gastric adenocarcinoma, high levels of EGF-R and Her-2/neu expression are associated with low overall survival. The reported range of Her2/neu expression varies widely, however (16)(17)(18)(19)(20)(21). This may be due to differences in patient selection, since Her-2/neu overexpression appears to be more common in advanced tumors rather than in early disease.…”

mentioning

confidence: 99%

Signal Transduction Proteins in Tumors From Puerto Rican and Caucasian Gastric Adenocarcinoma Patients: Expression Differences With Potential for Specific Targeted Therapies

Cangiano¹,

Centeno

Garrett

et al. 2008

Dig Dis Sci

View full text Add to dashboard Cite

Gastric cancer is the second cause of cancer death with approximately 800,000 annual new cases reported worldwide. The incidence of gastric adenocarcinoma has progressively increased, while 5-year survival rates of 20% have remained unchanged for several decades. New strategies for early detection and treatment remain a significant unmet medical need. Advances in our understanding of signal transduction mechanisms have led to novel treatment approaches in a variety of tumors. Over-expression of the HER2/NEU gene is associated with aggressive behavior and poor prognosis in breast cancer, and this has made the Her2/neu protein a target for directed therapy. Several reports indicate that there are ethnic differences in the clinical behavior of gastric cancer, but the reasons for this observation are not clearly understood. We have investigated potential differences in the expression of selected signal transduction proteins (Her2/neu, EGF-R, Cyclin D1 and p-Stat3) in gastric cancers from 100 Puerto Rican and 95 Caucasian patients. Puerto Rican patients had higher disease stages at presentation (Stage IV disease was observed in 44% of Puerto Ricans and in 18% of Caucasians). The majority of tumors in both populations showed over-expression of p-Stat3 but there were no statistical significant differences between the two groups. Her2/neu was over-expressed in the tumors of both patient populations but at higher HHS Public Access

show abstract

Membranous levels of c-erbB-2 oncoprotein in gastric cancer: Their relationship with clinicopathological parameters and their prognostic significance

Cited by 8 publications

References 25 publications

Clinicopathologic factors associated with HER2‐positive gastric cancer and its impact on survival outcomes—A systematic review

Clinicopathologic factors associated with HER2‐positive gastric cancer and its impact on survival outcomes—A systematic review

Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance

Signal Transduction Proteins in Tumors From Puerto Rican and Caucasian Gastric Adenocarcinoma Patients: Expression Differences With Potential for Specific Targeted Therapies

Contact Info

Product

Resources

About